1. Home
  2. NAZ vs BDTX Comparison

NAZ vs BDTX Comparison

Compare NAZ & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Arizona Quality Municipal Income Fund

NAZ

Nuveen Arizona Quality Municipal Income Fund

HOLD

Current Price

$12.58

Market Cap

162.0M

Sector

Finance

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.89

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAZ
BDTX
Founded
1992
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.0M
171.9M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
NAZ
BDTX
Price
$12.58
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.67
AVG Volume (30 Days)
19.6K
2.3M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
3.69%
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.50
$1.60
52 Week High
$13.42
$4.94

Technical Indicators

Market Signals
Indicator
NAZ
BDTX
Relative Strength Index (RSI) 46.37 46.63
Support Level $12.35 $1.60
Resistance Level $12.63 $2.30
Average True Range (ATR) 0.16 0.16
MACD 0.00 0.05
Stochastic Oscillator 51.21 47.15

Price Performance

Historical Comparison
NAZ
BDTX

About NAZ Nuveen Arizona Quality Municipal Income Fund

Nuveen Arizona Quality Municipal Income Fund is a closed-end management investment company. The Fund seeks to provide current income exempt from regular federal, New York State, and New York City income taxes, and from the federal alternative minimum tax for individuals, while enhancing portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds considered underrated, undervalued, or from undervalued municipal market sectors. It may invest in municipal securities such as lease obligations and certificates of participation, which provide an undivided interest in pools of municipal leases or installment purchase agreements.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: